Long-Term Follow-Up of Hypochondriasis After Selective Serotonin Reuptake Inhibitor Treatment
: There is paucity of knowledge on the long-term outcome of hypochondriasis, with even less knowledge about the effect of treatment with a selective serotonin reuptake inhibitor (SSRI). : This prospective follow-up study included 58 patients with Diagnostic and Statistical Manual of Mental Disorders...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical psychopharmacology 2011-06, Vol.31 (3), p.365-368 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 368 |
|---|---|
| container_issue | 3 |
| container_start_page | 365 |
| container_title | Journal of clinical psychopharmacology |
| container_volume | 31 |
| creator | SCHWEITZER, Pernilla J ZAFAR, Uzma PAVLICOVA, Martina FALLON, Brian A |
| description | : There is paucity of knowledge on the long-term outcome of hypochondriasis, with even less knowledge about the effect of treatment with a selective serotonin reuptake inhibitor (SSRI).
: This prospective follow-up study included 58 patients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) hypochondriasis who had participated in a trial of SSRI treatment 4 to 16 years earlier (mean ± SD = 8.6 ± 4.5 years).
: Information was obtained on 79.3% (n = 46) of the original group. At follow-up, 40% of the patients continued to meet full DSM-IV criteria for hypochondriasis. Persistence of hypochondriasis was individually predicted by longer duration of prior hypochondriasis (P = 0.003), history of childhood physical punishment (P = 0.01), and less usage of SSRIs during the interval period (P = 0.02). Remission status was not significantly predicted by demographic characteristics, baseline hypochondriasis severity, or psychiatric comorbidity.
: A substantial proportion of patients with hypochondriasis who receive treatment with SSRIs achieve remission over the long term. Interim SSRI use may be a factor contributing to better prognosis. |
| doi_str_mv | 10.1097/JCP.0b013e31821896c3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_904496475</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>904496475</sourcerecordid><originalsourceid>FETCH-LOGICAL-c368t-6808079ca28aaf9e071b52f73d34812f85fa7ad428115d8e9e8c0b6373f4daed3</originalsourceid><addsrcrecordid>eNpdkE1P3DAURa0KVAbaf1ChbKquAn62E9tLNCpfGglEB6mbKnKcZ3CbxMH2FPHvCWJaJFbvLs69TzqEfAF6BFTL48vl9RFtKXDkoBgoXVv-gSyg4ryUwH7ukAVlEkoqhd4j-yn9phSEZNVHssegokrVsCC_VmG8K9cYh-I09H14LG-nIrji_GkK9j6MXfQm-VScuIyx-IE92uz_4pxiyGH0Y3GDmymbP1hcjPe-9TnEYh3R5AHH_InsOtMn_Ly9B-T29Pt6eV6urs4ulier0vJa5bJWVFGprWHKGKeRSmgr5iTvuFDAnKqckaYTTAFUnUKNytK25pI70Rns-AH59ro7xfCwwZSbwSeLfW9GDJvUaCqEroWsZlK8kjaGlCK6Zop-MPGpAdq8eG1mr817r3PtcPtg0w7Y_S_9EzkDX7eASdb0LprR-vTGCVC11BV_BlSxggk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>904496475</pqid></control><display><type>article</type><title>Long-Term Follow-Up of Hypochondriasis After Selective Serotonin Reuptake Inhibitor Treatment</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>SCHWEITZER, Pernilla J ; ZAFAR, Uzma ; PAVLICOVA, Martina ; FALLON, Brian A</creator><creatorcontrib>SCHWEITZER, Pernilla J ; ZAFAR, Uzma ; PAVLICOVA, Martina ; FALLON, Brian A</creatorcontrib><description>: There is paucity of knowledge on the long-term outcome of hypochondriasis, with even less knowledge about the effect of treatment with a selective serotonin reuptake inhibitor (SSRI).
: This prospective follow-up study included 58 patients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) hypochondriasis who had participated in a trial of SSRI treatment 4 to 16 years earlier (mean ± SD = 8.6 ± 4.5 years).
: Information was obtained on 79.3% (n = 46) of the original group. At follow-up, 40% of the patients continued to meet full DSM-IV criteria for hypochondriasis. Persistence of hypochondriasis was individually predicted by longer duration of prior hypochondriasis (P = 0.003), history of childhood physical punishment (P = 0.01), and less usage of SSRIs during the interval period (P = 0.02). Remission status was not significantly predicted by demographic characteristics, baseline hypochondriasis severity, or psychiatric comorbidity.
: A substantial proportion of patients with hypochondriasis who receive treatment with SSRIs achieve remission over the long term. Interim SSRI use may be a factor contributing to better prognosis.</description><identifier>ISSN: 0271-0749</identifier><identifier>EISSN: 1533-712X</identifier><identifier>DOI: 10.1097/JCP.0b013e31821896c3</identifier><identifier>PMID: 21508861</identifier><identifier>CODEN: JCPYDR</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Adolescent ; Adult ; Adult and adolescent clinical studies ; Aged ; Biological and medical sciences ; Child Abuse - statistics & numerical data ; Clinical Trials as Topic ; Diagnostic and Statistical Manual of Mental Disorders ; Female ; Fluoxetine - therapeutic use ; Fluvoxamine - therapeutic use ; Follow-Up Studies ; Humans ; Hypochondriasis - diagnosis ; Hypochondriasis - drug therapy ; Male ; Medical sciences ; Middle Aged ; Neuropharmacology ; Personality Disorders - complications ; Personality Disorders - drug therapy ; Pharmacology. Drug treatments ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Remission Induction ; Serotonin Uptake Inhibitors - therapeutic use ; Severity of Illness Index ; Somatoform disorders. Psychosomatics</subject><ispartof>Journal of clinical psychopharmacology, 2011-06, Vol.31 (3), p.365-368</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c368t-6808079ca28aaf9e071b52f73d34812f85fa7ad428115d8e9e8c0b6373f4daed3</citedby><cites>FETCH-LOGICAL-c368t-6808079ca28aaf9e071b52f73d34812f85fa7ad428115d8e9e8c0b6373f4daed3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24186795$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21508861$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SCHWEITZER, Pernilla J</creatorcontrib><creatorcontrib>ZAFAR, Uzma</creatorcontrib><creatorcontrib>PAVLICOVA, Martina</creatorcontrib><creatorcontrib>FALLON, Brian A</creatorcontrib><title>Long-Term Follow-Up of Hypochondriasis After Selective Serotonin Reuptake Inhibitor Treatment</title><title>Journal of clinical psychopharmacology</title><addtitle>J Clin Psychopharmacol</addtitle><description>: There is paucity of knowledge on the long-term outcome of hypochondriasis, with even less knowledge about the effect of treatment with a selective serotonin reuptake inhibitor (SSRI).
: This prospective follow-up study included 58 patients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) hypochondriasis who had participated in a trial of SSRI treatment 4 to 16 years earlier (mean ± SD = 8.6 ± 4.5 years).
: Information was obtained on 79.3% (n = 46) of the original group. At follow-up, 40% of the patients continued to meet full DSM-IV criteria for hypochondriasis. Persistence of hypochondriasis was individually predicted by longer duration of prior hypochondriasis (P = 0.003), history of childhood physical punishment (P = 0.01), and less usage of SSRIs during the interval period (P = 0.02). Remission status was not significantly predicted by demographic characteristics, baseline hypochondriasis severity, or psychiatric comorbidity.
: A substantial proportion of patients with hypochondriasis who receive treatment with SSRIs achieve remission over the long term. Interim SSRI use may be a factor contributing to better prognosis.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Child Abuse - statistics & numerical data</subject><subject>Clinical Trials as Topic</subject><subject>Diagnostic and Statistical Manual of Mental Disorders</subject><subject>Female</subject><subject>Fluoxetine - therapeutic use</subject><subject>Fluvoxamine - therapeutic use</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Hypochondriasis - diagnosis</subject><subject>Hypochondriasis - drug therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neuropharmacology</subject><subject>Personality Disorders - complications</subject><subject>Personality Disorders - drug therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Remission Induction</subject><subject>Serotonin Uptake Inhibitors - therapeutic use</subject><subject>Severity of Illness Index</subject><subject>Somatoform disorders. Psychosomatics</subject><issn>0271-0749</issn><issn>1533-712X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkE1P3DAURa0KVAbaf1ChbKquAn62E9tLNCpfGglEB6mbKnKcZ3CbxMH2FPHvCWJaJFbvLs69TzqEfAF6BFTL48vl9RFtKXDkoBgoXVv-gSyg4ryUwH7ukAVlEkoqhd4j-yn9phSEZNVHssegokrVsCC_VmG8K9cYh-I09H14LG-nIrji_GkK9j6MXfQm-VScuIyx-IE92uz_4pxiyGH0Y3GDmymbP1hcjPe-9TnEYh3R5AHH_InsOtMn_Ly9B-T29Pt6eV6urs4ulier0vJa5bJWVFGprWHKGKeRSmgr5iTvuFDAnKqckaYTTAFUnUKNytK25pI70Rns-AH59ro7xfCwwZSbwSeLfW9GDJvUaCqEroWsZlK8kjaGlCK6Zop-MPGpAdq8eG1mr817r3PtcPtg0w7Y_S_9EzkDX7eASdb0LprR-vTGCVC11BV_BlSxggk</recordid><startdate>20110601</startdate><enddate>20110601</enddate><creator>SCHWEITZER, Pernilla J</creator><creator>ZAFAR, Uzma</creator><creator>PAVLICOVA, Martina</creator><creator>FALLON, Brian A</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>20110601</creationdate><title>Long-Term Follow-Up of Hypochondriasis After Selective Serotonin Reuptake Inhibitor Treatment</title><author>SCHWEITZER, Pernilla J ; ZAFAR, Uzma ; PAVLICOVA, Martina ; FALLON, Brian A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c368t-6808079ca28aaf9e071b52f73d34812f85fa7ad428115d8e9e8c0b6373f4daed3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Child Abuse - statistics & numerical data</topic><topic>Clinical Trials as Topic</topic><topic>Diagnostic and Statistical Manual of Mental Disorders</topic><topic>Female</topic><topic>Fluoxetine - therapeutic use</topic><topic>Fluvoxamine - therapeutic use</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Hypochondriasis - diagnosis</topic><topic>Hypochondriasis - drug therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neuropharmacology</topic><topic>Personality Disorders - complications</topic><topic>Personality Disorders - drug therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Remission Induction</topic><topic>Serotonin Uptake Inhibitors - therapeutic use</topic><topic>Severity of Illness Index</topic><topic>Somatoform disorders. Psychosomatics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SCHWEITZER, Pernilla J</creatorcontrib><creatorcontrib>ZAFAR, Uzma</creatorcontrib><creatorcontrib>PAVLICOVA, Martina</creatorcontrib><creatorcontrib>FALLON, Brian A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>Journal of clinical psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SCHWEITZER, Pernilla J</au><au>ZAFAR, Uzma</au><au>PAVLICOVA, Martina</au><au>FALLON, Brian A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-Term Follow-Up of Hypochondriasis After Selective Serotonin Reuptake Inhibitor Treatment</atitle><jtitle>Journal of clinical psychopharmacology</jtitle><addtitle>J Clin Psychopharmacol</addtitle><date>2011-06-01</date><risdate>2011</risdate><volume>31</volume><issue>3</issue><spage>365</spage><epage>368</epage><pages>365-368</pages><issn>0271-0749</issn><eissn>1533-712X</eissn><coden>JCPYDR</coden><abstract>: There is paucity of knowledge on the long-term outcome of hypochondriasis, with even less knowledge about the effect of treatment with a selective serotonin reuptake inhibitor (SSRI).
: This prospective follow-up study included 58 patients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) hypochondriasis who had participated in a trial of SSRI treatment 4 to 16 years earlier (mean ± SD = 8.6 ± 4.5 years).
: Information was obtained on 79.3% (n = 46) of the original group. At follow-up, 40% of the patients continued to meet full DSM-IV criteria for hypochondriasis. Persistence of hypochondriasis was individually predicted by longer duration of prior hypochondriasis (P = 0.003), history of childhood physical punishment (P = 0.01), and less usage of SSRIs during the interval period (P = 0.02). Remission status was not significantly predicted by demographic characteristics, baseline hypochondriasis severity, or psychiatric comorbidity.
: A substantial proportion of patients with hypochondriasis who receive treatment with SSRIs achieve remission over the long term. Interim SSRI use may be a factor contributing to better prognosis.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>21508861</pmid><doi>10.1097/JCP.0b013e31821896c3</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0271-0749 |
| ispartof | Journal of clinical psychopharmacology, 2011-06, Vol.31 (3), p.365-368 |
| issn | 0271-0749 1533-712X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_904496475 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adolescent Adult Adult and adolescent clinical studies Aged Biological and medical sciences Child Abuse - statistics & numerical data Clinical Trials as Topic Diagnostic and Statistical Manual of Mental Disorders Female Fluoxetine - therapeutic use Fluvoxamine - therapeutic use Follow-Up Studies Humans Hypochondriasis - diagnosis Hypochondriasis - drug therapy Male Medical sciences Middle Aged Neuropharmacology Personality Disorders - complications Personality Disorders - drug therapy Pharmacology. Drug treatments Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Remission Induction Serotonin Uptake Inhibitors - therapeutic use Severity of Illness Index Somatoform disorders. Psychosomatics |
| title | Long-Term Follow-Up of Hypochondriasis After Selective Serotonin Reuptake Inhibitor Treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T00%3A35%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-Term%20Follow-Up%20of%20Hypochondriasis%20After%20Selective%20Serotonin%20Reuptake%20Inhibitor%20Treatment&rft.jtitle=Journal%20of%20clinical%20psychopharmacology&rft.au=SCHWEITZER,%20Pernilla%20J&rft.date=2011-06-01&rft.volume=31&rft.issue=3&rft.spage=365&rft.epage=368&rft.pages=365-368&rft.issn=0271-0749&rft.eissn=1533-712X&rft.coden=JCPYDR&rft_id=info:doi/10.1097/JCP.0b013e31821896c3&rft_dat=%3Cproquest_cross%3E904496475%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=904496475&rft_id=info:pmid/21508861&rfr_iscdi=true |